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Conference Highlights
Epileptic encephalopathies, defined as syndromes in which seizures or epileptiform activity contribute to or exacerbate underlying brain dysfunction, represent one of the most daunting challenges in pediatric neurology. Although individually rare, the epileptic encephalopathies collectively exact an immense personal, medical, and financial toll on affected children and their families, healthcare providers, and the healthcare system. Yet, our understanding of the basic mechanisms, clinical consequences, and therapeutic options is limited. The Neurobiology of Diseases in Children symposium at the 2015 annual meeting of the Child Neurology Society aimed to further understand the clinical aspects, neurobiology, and pathogenesis, and therapeutic opportunities for treating epileptic encephalopathies in infants and children. This article summarizes some major points discussed at the symposium, with a focus on new findings and concepts that have translational relevance. Speakers discussed both individual syndromes and common features across syndromes, with the goal of establishing research priorities to improve the care and prognosis of affected children.
Conceptual Issues: Definition, Context, Diagnosis
The most recent International League Against Epilepsy (ILAE) Commission report defines epileptic encephalopathies as conditions in which epileptic activity itself contributes to severe cognitive and behavioral impairments above and beyond what might be expected from the underlying pathology alone, and that these impairments can worsen over time (1) . This definition has several important implications: 1) epileptic encephalopathies can be either static or progressive; 2) the seizures or EEG abnormalities such as interictal discharges can directly worsen cognition or behavior; and 3) treatment of the seizures or EEG abnormalities would be expected to improve the cognitive or behavioral deficits as well as reduce the seizures (2) . The new definition revises the former concept that epileptic encephalopathies are nonprogressive. Also implicit in the definition is that treatment of the seizures or spikes can allay the encephalopathy and improve cognitive function, at least in some cases. Nevertheless, failure of treatment to improve either seizures or encephalopathy is commonplace, as epileptic encephalopathies are highly resistant to treatment (3) . Furthermore, while the term epileptic encephalopathy implies a contribution of seizures or EEG abnormalities to the encephalopathy, the underlying etiology of the epileptic encephalopathy undoubtedly also plays a role in prognosis ( Figure 1 ). Some authors have argued that the term epileptic encephalopathy should be reserved for conditions in which the seizures or interictal discharges directly alter cognition (a process) rather than using this term to define any disorder that includes severe epilepsy and intellectual dysfunction (4, 5) . According to that view, an epileptic encephalopathy would refer to a process rather than a category of disease. For example, if a disorder in its earliest stages involves cognitive decline but relatively mild or infrequent seizures, this stage would not be considered an epileptic encephalopathy. Later in childhood, if seizures predominate and cognition declines in parallel, the disorder would be more consistent with an epileptic encephalopathy. It has been contended that some cases of Dravet syndrome fit this time course (4, 5) .
Clinical Aspects of Epileptic Encephalopathy Syndromes
Epileptic encephalopathies were originally classified by clinical features and EEG findings. Historically, prototypical epileptic encephalopathies have included Ohtahara syndrome (early infantile epileptic encephalopathy, EIEE), infantile spasms (West syndrome, WS), Lennox-Gastaut syndrome (LGS), severe myoclonic epilepsy of infancy (Dravet syndrome), and electrical status epilepticus in sleep (ESES)/Landau-Kleffner syndrome (LKS). Now, with the explosion of identified genetic, structural, and autoimmune causes of severe early-life epilepsy and intellectual disability, the list of presumed epileptic encephalopathies has expanded greatly.
It is remarkable that despite the multitude of etiologies, the resulting clinical phenotypes of some epileptic encephalopathies can be quite similar. For example, in WS, infantile spasms and hypsarrhythmia occur at a similar age and with similar manifestations, regardless of whether the etiology is perinatal hypoxia-ischemia or an ARX mutation. In summarizing clinical advances in WS, Susan Koh opined that there must be some common neurobiological basis to the multiple etiologies that engender a similar clinical phenotype. Evidence is accumulating that earlier detection, diagnosis, and treatment of infantile spasms are associated with less-severe outcomes, though the prognosis remains poor and is dependent on the etiology. A large multicenter database called the Pediatric Epilepsy Research Consortium (PERC) has been established recently, allowing researchers to pursue specific questions that would be untenable at a single institution (6) . Using PERC data, ongoing investigations are attempting to link treatment type and dose with etiology, clinical response, and prognosis. Infantile spasms is one of PERC's top research priorities.
The traditional criteria for LGS include multiple seizure types (mainly generalized; e.g., tonic, atypical absence, atonic, myoclonic), cognitive impairment, and abnormal EEG with slow spike-waves (1-2.5 Hz). Jim Wheless pointed out that not all patients exhibit this classic triad, and the three features need not occur at the same time. Furthermore, the manifestations of LGS vary over time. Seizure types may change as the patient matures, and the cognitive deficits can worsen with age even while seizures and EEG abnormalities abate as children with LGS enter adulthood (7) . The numerous acquired and genetic etiologies of LGS overlap with those leading to infantile spasms, and in a substantial proportion of each syndrome, a cause is not identified. The varied etiologies account for a large spectrum of clinical manifestations. The neurobiological basis for LGS likely involves the dysfunction of neural networks, especially disruption of integrated neural activity between subcortical (thalamus, brainstem) and association cortical areas, as demonstrated by functional neuroimaging (8) .
ESES, continuous spike-waves in sleep (CSWS), and acquired epileptic aphasia (LKS) comprise a spectrum of epileptic encephalopathies in which interictal discharges are thought to cause intellectual, language, or behavioral declines (9) . Eduo-ard Hirsch proposed that classic epileptic encephalopathies such as ESES, LKS, and CSWS are associated with more severe seizures and cognitive deficits, while benign epilepsy with central-temporal spikes (BECTS), characterized by focal seizures and sometimes subtle neurocognitive deficits, occupies the benign end of the spectrum (10) . In these syndromes, the localization of interictal (or ictal) spikes predicts specific forms of cognitive impairment: temporal lobe discharges could affect language (LKS), frontal lobe dysfunction could engender attentional and executive dysfunction and sometimes an autism-like picture, and central discharges as in BECTS might cause motor difficulties. Though most cases have an unknown etiology, there is an intriguing possible link with certain gene mutations and early structural lesions such as malformations of cortical development (11) . For example, mutations in the gene GRIN2A, involved in neural development and cell adhesion, have been identified in a spectrum of syndrome severity from mild (BECTS) to profound (LKS) (12) . An autoimmune etiology has also been proposed for ESES and LKS and may explain why corticosteroids are occasionally effective (13, 14) .
The autoimmune encephalopathies represent a fascinating group of disorders that have epilepsy as a prominent component, but they do not strictly conform to the definition of epileptic encephalopathy-in this set of antibody-mediated disorders, it is likely that the underlying etiology causes neurologic dysfunction, rather than the seizures themselves leading to cognitive decline. The explosion of knowledge about autoimmune encephalopathies was highlighted by Angela Vincent, who emphasized the phenotypic overlap of the various autoimmune encephalopathies, the best studied being the syndrome resulting from antibodies directed FIGURE 1. Conceptualization of the epileptic encephalopathies. The term epileptic encephalopathy has been defined by the ILAE as conditions in which epileptic activity itself contributes to severe cognitive and behavioral impairments above and beyond what might be expected from the underlying pathology (1) . Interictal discharges or seizures lead to encephalopathic changes consisting of cognitive impairment and increased seizure susceptibility. Numerous etiologies associated with epilepsy and intellectual disability would not necessarily fit this definition (hence the question mark), though the current literature does not always make this distinction. Implicit in the definition is that treatment of the epileptiform abnormalities (or possibly treatment of the etiology) could avert or ameliorate the encephalopathic outcome. Mechanisms underlying each component of this diagram need to be elucidated. against the NMDA receptor (15) . The intriguing convergence of mechanisms is illustrated by the above-mentioned GRIN2A mutations in ECTS/ESES/LKS, which also affect NMDA-receptor subunits (16) .
Neurobiology and Pathogenesis
The mechanisms by which seizures or interictal discharges affect the brain at various stages in development have fundamental implications for the epileptic encephalopathies. It is well established that the immature brain is more susceptible to seizure generation than the adult brain, yet the developing brain is more resilient to long-term consequences such as subsequent epilepsy, cognitive impairment, and structural damage, a reflection of the developing brain's neuroplasticity (17, 18) . It has been challenging to create realistic animal models of complex disorders such as the epileptic encephalopathies, since humans and experimental systems differ on many levels. However, preclinical studies can address specific mechanistic and therapeutic questions (19) .
As above, epileptic encephalopathies are viewed as the slowing or regression of development primarily due to seizures or abnormal interictal cortical and subcortical activity, or both, and not due primarily to the underlying cause of the seizures (18) . Recent research using animal models has focused on the timing of interictal discharges with respect to cognitive responses. Greg Holmes discussed a Dravet syndrome model in which mice were genetically engineered with downregulated sodium channels (NaV1.1) only in basal forebrain, a network involved in learning and memory (20) . In this model, mice showed cognitive deficits but no spontaneous seizures, leading to the conclusion that the genetic etiology (NaV1.1 mutation), not seizures, is most responsible for the cognitive impairment (20) .
The hippocampus is a major site of memory processing in the brain as well as being uniquely susceptible to seizure generation. Place cells are a type of hippocampal neuron that is sensitive to an animal's location in space-place cells fire only when an animal enters a certain location. The effects of interictal spikes on behavior and cognition were tested using place-cell firing as an assay (21) . Interictal spike occurrence and timing were precisely correlated with transient impairment of cognitive performance on tests such as the delayed matching-to-sample task that primarily measures memory retrieval. In the case of epileptic encephalopathies, with frequently occurring interictal spikes, it is straightforward to envision how discharges impair ongoing cognitive responses (22) . Furthermore, early-life seizures disrupt place-cell stability and the ability of animals to learn and remember spatial location (23) . Communication between brain regions responsible for a variety of cognitive tasks is mediated by a variety of intrinsic brain rhythms. The phase coherence between oscillations in neural networks may underlie cognitive impairments in the epileptic encephalopathies (8, 18) .
Inflammatory responses are a recurring theme in the epileptic encephalopathies. Neuroinflammation following seizures can both trigger brain dysfunction and serve as a potential target of therapy (24) . Sookyong Koh described a positive feedback cycle between brain inflammation and epileptogenesis: seizures and brain injury increase inflammation, and those proinflammatory changes in turn heighten seizure susceptibility and neuronal excitability (25) . Microglia are immune cells present in the brain that become activated rapidly with a brain injury such as seizure. Postnatal development of microglia correlates closely with seizure susceptibility (26) . In addition, blood-brain barrier compromise allows components of the peripheral immune system to enter the brain. Brain inflammation can be ameliorated by anti-inflammatory medications such as steroids and minocycline, and by environmental enrichment. In animal models, specific inflammatory pathways are being targeted to attenuate seizure-induced increases in inflammation-related genes as well as to decrease the susceptibility of animals to subsequent seizures. These mechanisms may well play a role in preventing epileptogenesis in the developing brain (25) . For example, dexamethasone, minocycline treatment, and environmental enrichment all prevent the priming effect of early-life seizures on subsequent seizure susceptibility by retarding the activation of microglia. These promising experimental findings await clinical correlation in the epileptic encephalopathies.
As emphasized above, the causes of epileptic encephalopathy can range from a single gene mutation (e.g., a mutation of SCN1A in Dravet syndrome) to numerous symptomatic etiologies (e.g., West syndrome) (27, 28) . Tallie Baram considered several levels of neuronal function that might be affected by a monogenic mutation or neuronal injury, including direct effects on membrane properties, dysfunction of ion channels or synapses, injury to or death of certain cell types leading to network dysfunction, and epigenetic changes (29) . Early-life events such as fever, infection, or stress can ultimately dictate the phenotype via the genome and epigenome (29) . Epigenetic processes govern the function of the genome by chromatin conformational changes, gene transcription, and translation and mRNA degradation via noncoding RNAs. Genetic and acquired insults impair the function of neuronal networks by changing the properties of neurons and glia. Therefore, epigenetic mechanisms are appropriate candidates to execute these large-scale changes and render them persistent, possibly via the activation of inflammation cascades (30) . In addition, neuronal excitability and network function are intimately dependent on metabolic pathways, themselves regulated by epigenetic factors (31) . Therefore, epigenetic mechanisms might provide targets for intervention in the development of epileptic encephalopathies of diverse origins.
In summary, epileptic encephalopathies are ultimately disorders of brain networks. Nonneuronal factors in epileptic encephalopathy pathogenesis include the activation of inflammation as a result of neuronal injury or death and deficits in glial functions that lead to synaptic or metabolic derangements. Inflammation may contribute to epileptic encephalopathies through numerous pathways. Recently it has been shown that glia and neurons interact closely to regulate neuronal metabolism, which influences the normal functions of neurons and neuronal networks (32) .
Therapeutic Targets, Translational Opportunities, and Prognosis
Epileptic encephalopathies are notoriously difficult to treat and are often medically refractory from the onset (3). Since conventional antiseizure medicines are often unsuccessful, alternatives such as hormone therapy (adrenocorticotrophic hormone [(ACTH], corticosteroids) are often tried (33) . The goal of treating epileptic encephalopathies is to control seizures and prevent or reverse neurologic loss of function and cognitive and behavioral deficits. This all-or-none control of epileptiform patterns is certainly the goal in infantile spasms treatment but is achieved less often in LGS and ESES/LKS (3) .
Treatment of infantile spasms has a long history of controversy, as discussed by Susan Koh and Shlomo Shinnar (34, 35) . For the subset of infantile spasms patients with tuberous sclerosis complex, vigabatrin is the well-accepted first-line agent (36) . For patients with other etiologies, both ACTH and oral corticosteroids have some efficacy. Clinicians choose a therapy based upon effectiveness but resource allocation also needs to be considered (37) (38) (39) . Studies have compared doses of each agent and duration of treatment, but there is no universally agreed-upon protocol. In a recent study, 27 children with infantile spasms were treated with high-dose prednisolone (8 mg/kg/d for 2 weeks); 17 patients responded completely. Four of the ten prednisolone nonresponders experienced complete spasm control when switched to ACTH (40) . Earlier treatment seems more effective for both spasms cessation and cognitive outcome (41) . It is hoped that PERC data will lead to a more optimal protocol (42) .
Treatment options for LGS are also insufficient (43, 44) . Little evidence-based therapy is available for treating LGS, and a large portion of treatment is based on anecdotes, small case series, or expert opinion (44, 45) . Cognitive and behavioral outcomes have been rarely used as outcome variables in drug trials, and there are no good comparative effectiveness trials after the first monotherapy trial. While newer agents such as clobazam offer benefit for some patients (46) , most LGS patients are placed on multiple antiseizure drugs, leading to drug interactions; some drugs can even exacerbate seizures. The ketogenic diet and its variants (modified Atkins diet, low glycemic index treatment) can be useful (47) , and targeted surgical approaches (vagus nerve stimulation, corpus callosotomy) are sometimes beneficial (48) .
Treatment of ESES/LKS has likewise been suboptimal. Steroids and immune modulators have been the mainstay of treatment and high-dose benzodiazepines provide at least short-term efficacy (11) . A randomized European trial of steroids versus clobazam, called RESCUE ESES, is currently recruiting subjects. Small series suggest a benefit from surgical approaches such as multiple subpial transection, but only a small number of patients has been treated surgically and a wide variety of surgical techniques has been used, preventing a broad consensus from emerging (49) . The purported efficacy of surgical transections could inform pathophysiological considerations in these syndromes, with an implication that disruption of aberrant cortical-reticular-thalamic connections improves brain function (50) .
Treatment options for autoimmune encephalopathies overlap those for other epileptic encephalopathies (15, 51) . The goal of improving cognitive function as well as reducing seizures has been approached by altering the immune response. First-line treatment would entail corticosteroids, intravenous gamma globulins, or plasmapheresis. Second-line treatments would include immunosuppression with cyclophosphamide or rituximab. Consensus guidelines are lacking currently.
A major limitation of current antiseizure treatment for epileptic encephalopathies is that most patients remain uncontrolled despite numerous medication trials and drug resistance readily develops. In addition, no disease-modifying therapy is available to alter the process of epileptogenesis and prevent the development or progression of epilepsy, rather than just control seizures. Antiepileptogenic approaches would target some aspect of the process by which the brain becomes epileptic, such as specific cell-signaling pathways, cells, or circuits. An example of a potential molecular target for therapy of epileptic encephalopathies is the mechanistic target of rapamycin (mTOR), outlined by Michael Wong (52) . mTOR is a master regulator of cell growth and proliferation, under the control of tumor suppressor genes TSC1 and TSC2. mTOR is central in the pathogenesis of tuberous sclerosis complex (TSC) as well as other epilepsies (including acquired causes such as closed-head injury) and other neurologic disorders. The mTOR signaling pathway can be modified by compounds such as rapamycin, which inhibits the effects of mTOR on cellular regulation. The mTOR inhibitor everolimus (a rapamycin analog) decreases the size of subependymal giant-cell astrocytomas in TSC and is approved for use in that indication; it has also shown some promise in TSC patients with intractable epilepsy (53) . In animal models, rapamycin given early prevents seizure development, and when given to animals with existing epilepsy, rapamycin reduces seizure frequency. mTOR inhibition represents a rational approach to intractable epilepsy (52, 54) . The confluence of mechanisms is illustrated by the seizure-reducing effect of anti-inflammatory therapy in TSC1 conditional knock-out mice (55) .
Pluripotent stem cells, which give rise to all cells of an organism, are being investigated as a novel approach to epilepsy therapy (56) . Somatic cells are obtained from a patient and are then dedifferentiated in culture into stem cells that can subsequently be induced to form specific cell types (e.g., neurons, glia). In patients with neurologic diseases, induced pluripotent stem cells (iPSCs) can be used to examine disease mechanisms, test for drug response or toxicity, or screen for novel therapies. Jack Parent shared exciting results from his laboratory using iPSCs from patients with different SCN8A mutations; these children had severe epilepsy and intellectual disability (57) . Their iPSCs were used to determine which anti-seizure drugs were most effective in suppressing seizure activity in vitro, and this correlated with clinical response. Eventually, it might be possible to graft iPSC-derived cells (e.g., GABAergic cells that enhance neuronal inhibition) at specific stages of neural development to replace mutated, dysfunctional cells (58) . This would represent a truly "personalized" medicine approach. The relevance of this technique for the spectrum of epileptic encephalopathies is not yet clear, and several technical hurdles must be overcome before this technique becomes clinically feasible (59) .
Cannabis-based treatment for intractable epilepsy has been the subject of immense media interest, largely driven by anecdotal parental reports of success using a variety of cannabis derivatives. Families that have exhausted conventional antiseizure medications are often eager to try alternative approaches. There is some mechanistic rationale as innate endocannabinoid receptors modulate synaptic transmission (in a very complex and not fully understood manner) and some effectiveness has been reported in animal models (60) . However, as discussed by Amy Brooks-Kayal, rigorous data about the safety and effectiveness of cannabis are scant. There have been a few small trials (mainly class IV studies), all with methodologic deficiencies making conclusions difficult (61, 62) . Cannabis is not rigorously regulated, and the numerous derivatives from the cannabis plant (e.g., cannabidiol, delta-9-tetrahydrocannabinol) have engendered a bewildering complexity of variables. A recent prospective, open-label multicenter trial involving 214 patients with intractable epilepsy (many with epileptic encephalopathies such as LGS or Dravet syndrome) used relatively pure cannabinoid oil to test its safety, tolerability and efficacy (63) . More than 10% of patients had side effects such as somnolence, decreased appetite, or diarrhea. Median seizure frequency in this intractable population was decreased by 36.5% at 12 weeks. Randomized controlled studies are necessary and potential CNS toxicity remains a concern. It has been observed that cannabinoids may interfere with learning and memory, sleep, and mood regulation. Regulatory issues also remain substantial, with state legislatures varying greatly in their policies regarding medical marijuana. There is a lack of data on the safety, efficacy, clinical pharmacokinetics, and drug interactions and no standardization of content, quality, or purity of products. Nevertheless, cannabinoids remain appealing to families with few other choices, especially for children who have been through numerous medication trials, dietary therapies, and other treatments. Future research is obviously critical to understand the place that cannabinoids might occupy in the treatment of epileptic encephalopathies. The role of cannabinoids in suppressing seizures is uncertain, but the dramatic increase in its use has sparked a dedicated research effort to define the mechanisms.
Future Directions
To conclude the symposium, an expert panel, moderated by Brandy Fureman, considered a variety of future directions in diagnosis and treatment of epileptic encephalopathies. Topics included new pharmacologic approaches to the epileptic encephalopathies (Jacqueline French, Jack Pellock, Lionel Carmant), including metabolism-based therapies such as the ketogenic diet (Eric Kossoff ). Jack Pellock underscored the importance of considering a family's wishes and perception of their child's quality of life as important outcome measures. Eric Kossoff emphasized several reasons why dietary therapies are worth considering in the epileptic encephalopathies, including the refractoriness of seizures to conventional medications, the cumulative adverse effects of polypharmacy, and the onset during infancy. It is hoped that the rapid expansion in identification of genetic causes of epileptic encephalopathies (Anna Poduri) will lead to greater understanding of pathophysiological mechanisms and treatment based on specific etiologies (Aristea Galanopoulou). Overall, better guidelines are needed for treatment of epileptic encephalopathies, and there is a dire need for novel therapies, especially those that are etiology specific and address both cognitive changes and seizure control (64) .
